Oncology Clinical Service Line
System-wide Consensus Guidelines: **Pathological Evaluation of the Axillary Sentinel Lymph Nodes in Patients Undergoing Lumpectomy and Radiation Therapy**

These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable for all patients

Reference #: SYS-PC-OCSL-CG-013

Origination Date: June 2014
Next Review Date: 2021
Effective Date: 2018

Approved Date:
Approval By:

**System-wide Ownership Group:** Allina Health Breast Program Committee

**System-wide Information Resource:** Manager of Clinical Programs

| Hospital Division Quality Council: August 2018 |
| **Stakeholder Groups** |
| Virginia Piper Cancer Institute |

**SCOPE:**

<table>
<thead>
<tr>
<th>Sites, Facilities, Business Units</th>
<th>Departments, Divisions, Operational Areas</th>
<th>People applicable to</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Northwestern Hospital, Buffalo Hospital, Cambridge Medical Center, District One Hospital, Mercy Hospital, Mercy Hospital – Unity Campus, New Ulm Medical Center, River Falls Area</td>
<td>Breast Surgeons, Pathology, Radiation Oncology, Medical Oncology</td>
<td>Physicians, Advanced practice providers</td>
</tr>
</tbody>
</table>

Guidelines are not meant to replace clinical judgment or professional standards of care. Clinical judgment must take into consideration all the facts in each individual and particular case, including individual patient circumstances and patient preferences. They serve to inform clinical judgment, not act as a substitute for it. These guidelines were developed by a Review Organization. These guidelines may be disclosed only for the purposes of the Review Organization according to Minn. Statutes §145.64 and are subject to the limitations described at Minn. Statutes §145.65
**PICO (TS) Framework**

**Population:** Breast cancer patients undergoing lumpectomy and sentinel lymph node (SLN) biopsy, followed by radiation therapy.

**Intervention:** Evaluation of the axillary sentinel nodes at the time of lumpectomy, and on subsequent permanent section evaluation by immunohistochemistry (IHC)

**Comparison:** N/A

**Outcomes:**

1. Routine frozen section evaluation of the SLNs in patients undergoing lumpectomy for invasive breast cancer (who have not had neoadjuvant chemotherapy) is not routinely performed unless there is clinical evidence of gross disease within the lymph nodes, matted nodes, or 3 or more involved nodes.
2. Frozen section of SLNs is generally performed in patients undergoing lumpectomy following neoadjuvant chemotherapy.
3. The evaluation of SLNs by immunohistochemistry (IHC) is not routinely performed. However, IHC stains may be performed at the discretion of the pathologist (such as to evaluate atypical cells identified on H&E stains which require further clarification).

**Timing:** During initial breast surgery

**Setting:** Inpatient/hospital

**CLINICAL PRACTICE GUIDELINES:**

1. Routine frozen section is not recommended for the evaluation of the sentinel lymph nodes (SLNs) in most patients with invasive breast cancer undergoing breast conservation therapy (BCT) followed by whole breast radiation therapy.
2. Routine frozen section of SLNs is generally recommended for patients undergoing BCT who have undergone neoadjuvant chemotherapy.
3. Routine frozen section is currently recommended for the evaluation of the SLN in patients with invasive breast cancer undergoing mastectomy.
4. Patients with clinical T1 or T2 N0M0 undergoing BCT with < 3 positive SLN’s generally do not require axillary lymph node dissection (ALND)., assuming they undergo radiation therapy. Patients undergoing BCT with ≥3 positive SLNs, “gross” clinical disease, or matted nodes should be advised to undergo ALND.
5. The evaluation of the axillary sentinel nodes by immunohistochemistry (IHC) will not be routinely performed on SLNs. However, IHC stains may be performed at the discretion of the pathologist (in attempts to clarify atypical cells seen on routine H&E levels).

6. Controversial cases should be discussed in a multi-disciplinary breast conference.

**SUPPORTING EVIDENCE:**
The use of the SLN biopsy procedure was begun in the 1990s, and has become the standard for staging the axilla in breast cancer patients. Several large national studies have established the use of the SLN biopsy procedure, with a false negative rate of 3-5%. Immunohistochemical cytokeratin staining of the SLN was also begun in the 1990s, as an adjunct to the H&E evaluation of the SLN. The detection of even a single cancer cell by IHC in a SLN established its sensitivity and specificity in identifying possible metastatic disease.

More recent studies have questioned the significance of detecting isolated tumor cells (ITC) in the SLN in the staging and treatment of breast cancer patients. Several national studies have shown no difference in survival or recurrence in patients with negative SLN (without IHC staining) from those patients with positive SLN containing ITC’s who underwent ALND. In addition, some studies found no significant survival difference in patients with ITC from those with metastatic tumor deposits < 0.02 cm (micrometastases).

These studies questioned the use of IHC in the staging of the axilla for breast cancer patients. ALND causes considerable morbidity for patients with breast cancer including risk of lymphedema, musculoskeletal disability, infection and pain.

The ACOSOG Z0011 trial, published in 2010, was designed to determine whether ALND was necessary after detection of metastases in the SLN in patients undergoing breast conservation therapy (BCT) with whole breast radiation. Patients with a positive SLN were randomized to axillary dissection or no further axillary surgery. The patients enrolled in this trial were a select group of patients. Only patients with clinical T1 or T2N0M0 staged tumors were included. Most patients had a tumor size that was smaller than 2 cm. If patients had suspicious lymph nodes by exam, they were not included in this study. Additionally, if patients had 3 or more positive sentinel lymph nodes, extra-nodal disease or had neoadjuvant therapy, they were excluded from the study. IHC staining was not used in this study thus eliminating ITC’s as a factor in the staging of the axilla. SLN’s were evaluated by standard H&E staining techniques.

At a median follow-up of 6.3 years, there was no significant difference in loco-regional recurrence, 4% for axillary dissection vs. 2.8% for SLN alone. Overall survival was the same between both groups as well at 92%.
There are several important features to this study that need to be emphasized. First, this study did not include patients undergoing mastectomies. At present the standard of care for patients treated with mastectomy is to perform a sentinel lymph node biopsy; if the sentinel lymph node is positive then an axillary dissection should be recommended. Second, over 95% of patients had either chemotherapy and/or endocrine therapy. It is important for patients to understand the best outcomes for treating breast cancer occur when a multidisciplinary approach is used. If patients are unwilling to receive whole breast radiation, or chemotherapy/endocrine therapy then those patients may still benefit from an axillary dissection. Third, the patients in this study had very early staged cancers, small tumors with no evidence of lymph node involvement by exam.

There have been recent reviews that have yielded similar results, supporting eliminating axillary dissection for early staged breast cancer.(18).

Table 1 shows the results of 3 studies that show similar axillary recurrence rates for observation vs. axillary dissection, observation vs. axillary radiation, and axillary dissection vs. axillary radiation. After a median of 5 year follow-up, recurrence rates are less than 3%.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>ALND vs obs</th>
<th>AxRT vs obs</th>
<th>ALND vs AxRT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author</td>
<td>Martelli 2005</td>
<td>Veronesi 2005</td>
<td>Louis 2004</td>
</tr>
<tr>
<td>Study population</td>
<td>T1, &gt;70 y.o.</td>
<td>T1, &gt;45 y.o.</td>
<td>T&lt;3cm, &lt;70 y.o.</td>
</tr>
<tr>
<td>N</td>
<td>219</td>
<td>435</td>
<td>658</td>
</tr>
<tr>
<td>Median F/U</td>
<td>5</td>
<td>5.3</td>
<td>15</td>
</tr>
<tr>
<td>Axillary Recurrence</td>
<td>0 vs 1.8%</td>
<td>0.5% vs 1.5%</td>
<td>1% vs 3%</td>
</tr>
</tbody>
</table>

Bilomoria et al reviewed the NCDB database and retrospectively compared recurrence rates and survival for patients with positive SLN and no further axillary dissection vs. positive SLN followed by axillary dissection. Results are displayed in Table 2. There again was no difference between the two groups.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Axillary LR</th>
<th>5yr survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLN Micrometastases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Guidelines are not meant to replace clinical judgment or professional standards of care. Clinical judgment must take into consideration all the facts in each individual and particular case, including individual patient circumstances and patient preferences. They serve to inform clinical judgment, not act as a substitute for it. These guidelines were developed by a Review Organization. These guidelines may be disclosed only for the purposes of the Review Organization according to Minn. Statutes §145.64 and are subject to the limitations described at Minn. Statutes §145.65.
The recommendations of the Allina Health Breast Program Committee are based on these studies and the recommendations made by the authors of the “Z-11” study. Patients with <3 positive SLN’s who are undergoing BCT followed by whole breast radiation therapy will not routinely require ALND. These recommendations do not currently apply to patients undergoing mastectomy.

The detection of ITC’s in the SLN by IHC staining does not affect survival or locoregional recurrence. Therefore IHC will not be routinely used for the evaluation of the SLN. This applies to both patients undergoing BCT and mastectomy. Rare exceptions may occur, such as the evaluation of atypical cells within the sentinel node.

Since frozen section of the axillary SLN is used primarily for the detection of minimal disease in the SLN, and the Z-11 trial has shown that ALND for minimal disease in the axilla does not improve survival or recurrence in patients undergoing BCT followed by whole breast RT and adjuvant therapy, routine frozen section of the SLN is not recommended for patients undergoing BCT (exceptions listed above). However, frozen section evaluation of SLN will be used for patients having mastectomy.

These recommendations do not apply to patients who have had neoadjuvant therapy.

**ADDENDUM:**

Guidelines are not meant to replace clinical judgment or professional standards of care. Clinical judgment must take into consideration all the facts in each individual and particular case, including individual patient circumstances and patient preferences. They serve to inform clinical judgment, not act as a substitute for it. These guidelines were developed by a Review Organization. These guidelines may be disclosed only for the purposes of the Review Organization according to Minn. Statutes §145.64 and are subject to the limitations described at Minn. Statutes §145.65.
Guidelines are not meant to replace clinical judgment or professional standards of care. Clinical judgment must take into consideration all the facts in each individual and particular case, including individual patient circumstances and patient preferences. They serve to inform clinical judgment, not act as a substitute for it. These guidelines were developed by a Review Organization. These guidelines may be disclosed only for the purposes of the Review Organization according to Minn. Statutes §145.64 and are subject to the limitations described at Minn. Statutes §145.65

Metric: % patients undergoing BCT for invasive breast cancer who have a frozen section of the SLN (with the understanding that frozen section is indicated for certain subgroups of patients, including those undergoing neoadjuvant therapy).

Who will be measured for guideline adherence?
- All sites performing breast surgeries

What will be measured?
- % patients who underwent BCT for invasive breast cancer at an Allina facility with the SLN(s) evaluated by frozen section at the time of surgery (patients who have had neoadjuvant chemotherapy prior to surgery will be excluded).

Where is the data located?
- EDW/ERS

How will adherence be monitored?
- Monitored by Breast Program Committee

When will adherence data be collected?
- Minimally every year

REFERENCES:

Guidelines are not meant to replace clinical judgment or professional standards of care. Clinical judgment must take into consideration all the facts in each individual and particular case, including individual patient circumstances and patient preferences. They serve to inform clinical judgment, not act as a substitute for it. These guidelines were developed by a Review Organization. These guidelines may be disclosed only for the purposes of the Review Organization according to Minn. Statutes §145.64 and are subject to the limitations described at Minn. Statutes §145.65


Alternate Search Terms:

Related Guidelines/Documents

<table>
<thead>
<tr>
<th>Name</th>
<th>Content ID</th>
<th>Business Unit where Originated</th>
</tr>
</thead>
</table>

Guidelines are not meant to replace clinical judgment or professional standards of care. Clinical judgment must take into consideration all the facts in each individual and particular case, including individual patient circumstances and patient preferences. They serve to inform clinical judgment, not act as a substitute for it. These guidelines were developed by a Review Organization. These guidelines may be disclosed only for the purposes of the Review Organization according to Minn. Statutes §145.64 and are subject to the limitations described at Minn. Statutes §145.65.